Treatments for Menopause Symptoms: A Complete Patient Guide

Menopause symptoms are treated with menopausal hormone therapy, non-hormonal medicines, vaginal therapies, and lifestyle changes. The best fit depends on the symptom, whether you still have a uterus, your age, time since menopause, and risks such as blood clots, stroke, breast cancer, liver disease, and heart disease 1.

What symptoms of menopause actually need treatment?

Menopause symptoms need treatment when they disrupt sleep, sex, mood, work, daily comfort, or long-term health. Some people have mild symptoms for a short time, while others have symptoms for several years around perimenopause and postmenopause 2.

Hot flashes and night sweats

Hot flashes and night sweats are called vasomotor symptoms. They happen when changing estrogen levels affect the brain’s temperature-control system, making a normal room feel suddenly too hot 2.

Treatment can help when hot flashes wake you up, cause sweating through clothing, or make work and social life harder. Menopausal hormone therapy, also called hormone replacement therapy or HRT, has the strongest evidence for these symptoms, while non-hormonal medicines are useful when hormones are not a fit 1.

Vaginal dryness and painful sex

Vaginal dryness, burning, urinary urgency, recurrent urinary discomfort, and painful sex are part of genitourinary syndrome of menopause. Unlike hot flashes, these symptoms often continue unless treated because the vaginal and urinary tissues remain estrogen-sensitive after menopause 1.

Options include lubricants, moisturizers, low-dose vaginal estrogen, vaginal prasterone, and ospemifene. These are different from systemic hormone therapy because they focus on vaginal and urinary tissues rather than whole-body hot flash control 1.

Sleep problems and mood changes

Sleep trouble may come from night sweats, anxiety, mood changes, pain, sleep apnea, alcohol, or other causes. Treating night sweats can improve sleep for some people, but new depression, severe anxiety, or unsafe thoughts need prompt medical care 2.

Bone loss and long-term risks

Estrogen loss speeds bone loss after menopause and raises osteoporosis risk. Systemic hormone therapy can help prevent bone loss in appropriate candidates, but it is not the only bone-health option, and risks must be weighed with a clinician 1.

How do doctors decide who should be treated?

Treatment choice starts with three questions: where you are in the menopause transition, whether you have a uterus, and what health risks you carry. The often-cited under-60 or within-10-years window matters because benefit-risk balance tends to be more favorable earlier after menopause 1.

Perimenopause vs. postmenopause

Perimenopause is the transition time when periods become irregular and symptoms may begin. Postmenopause starts after 12 months without a menstrual period, unless another medical reason explains the bleeding pattern 2.

This matters because irregular bleeding, pregnancy risk, fibroids, thyroid disease, medication effects, and other issues can overlap with menopause symptoms. A clinician may ask about bleeding patterns, migraines, clot history, cancer history, family history, and current medicines before discussing treatment 1.

The under-60 / within-10-years window

The Menopause Society states that, for healthy symptomatic women younger than 60 or within 10 years of menopause onset, the benefit-risk ratio is generally favorable for treatment of bothersome vasomotor symptoms and prevention of bone loss 1.

For people older than 60 or more than 10 years from menopause onset, absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia are higher, so decisions need more caution and clearer goals 1.

Do you still have a uterus?

If you still have a uterus, systemic estrogen is usually paired with a progestogen, such as micronized progesterone or another progestin. This lowers the risk of overgrowth of the uterine lining that can occur with unopposed estrogen 1.

If your uterus was removed, estrogen-only therapy may be considered because endometrial protection is usually not needed. This difference is one reason a hormone plan should be based on your surgical and bleeding history, not symptoms alone 1.

What is menopausal hormone therapy (MHT/HRT)?

Menopausal hormone therapy, or HRT, means using estrogen with or without a progestogen to treat menopause-related symptoms. It can be systemic for hot flashes and night sweats, or local for vaginal and urinary symptoms, and it comes in several forms 1.

Estrogen-only therapy

Estrogen-only therapy may use estradiol or conjugated estrogens. It is usually considered for people without a uterus because estrogen alone can stimulate the uterine lining when the uterus is still present 1.

In the Women’s Health Initiative estrogen-alone trial, conjugated equine estrogen was studied at 0.625 mg daily in postmenopausal women with prior hysterectomy; the trial found increased stroke risk and lower hip fracture risk during the intervention period 4. Individual risk can differ from trial averages.

Combined estrogen plus progestogen

Combined estrogen-progestogen therapy pairs estrogen with a progestogen, such as micronized progesterone or a synthetic progestin. The progestogen is included to protect the uterine lining in people with a uterus 1.

In the Women’s Health Initiative combined-therapy trial, conjugated equine estrogen 0.625 mg plus medroxyprogesterone acetate 2.5 mg daily was studied in postmenopausal women with a uterus; the trial reported increased risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism, plus lower fracture and colorectal cancer risks 3. Those data are important, but they do not answer every question about lower doses, different routes, or different progestogens.

Systemic pill, patch, gel, spray, or ring

Systemic estrogen can be delivered by mouth or through the skin with a patch, gel, or spray. Some rings deliver systemic estrogen, while others are low-dose vaginal products mainly for local symptoms 1.

Route can matter. Observational evidence and society guidance suggest transdermal estrogen may have lower blood-clot and stroke risk than oral estrogen for some patients, but personal risk factors still matter 1.

Low-dose vaginal estrogen

Low-dose vaginal estrogen comes as a cream, tablet, ring, or insert. It is used for genitourinary syndrome of menopause, including dryness and painful sex, and it usually results in lower whole-body estrogen exposure than systemic therapy 1.

What are the risks and benefits of hormone therapy?

Hormone therapy benefits can include fewer hot flashes, less night sweating, improved vaginal symptoms when the right route is used, and bone-loss prevention. The key trade-off is that risks can include blood clots, stroke, gallbladder disease, and certain cancers, depending on the person and regimen 1.

Updated safety labeling and what it means

FDA-approved estrogen and estrogen-progestin products carry boxed warnings based largely on Women’s Health Initiative findings. The warnings address cardiovascular events, breast cancer for combined therapy, endometrial cancer risk with unopposed estrogen, and dementia risk in older postmenopausal women 5.

These warnings are not meant to say every patient has the same risk. They are a reminder that hormones should be used for a clear goal, at an appropriate dose and route, with regular reassessment 1.

Who should not take hormone therapy

Systemic hormone therapy is usually avoided in people with unexplained vaginal bleeding, active or prior estrogen-sensitive cancer, prior blood clot or stroke, active liver disease, known thrombophilia, or high-risk heart disease unless a specialist determines otherwise 1.

This is why a good menopause visit is not just a symptom checklist. It should include your bleeding history, cancer history, clot history, migraine history, blood pressure, tobacco use, family history, and current medications 1.

Oral vs. transdermal safety differences

Oral estrogen goes through the liver first, which can affect clotting proteins and triglycerides. Transdermal estrogen enters through the skin and may be preferred by some clinicians for patients with certain metabolic or clot-risk concerns, though individual risks still guide the plan 1.

What non-hormonal medicines treat menopause symptoms?

Non-hormonal treatments can reduce hot flashes or help vaginal symptoms when hormone therapy is not wanted or is not a good fit. They are not risk-free, and each option has specific side effects to review 10.

Fezolinetant for hot flashes

Fezolinetant is a neurokinin 3 receptor antagonist. In plain English, it acts on a brain pathway involved in temperature control, which is different from adding estrogen 6.

The FDA-approved fezolinetant label lists 45 mg by mouth once daily for moderate to severe vasomotor symptoms due to menopause. Labeling also describes liver blood-test monitoring and warns against use in people with known cirrhosis, severe kidney impairment, or end-stage kidney disease 6.

SSRIs and SNRIs

Paroxetine is a selective serotonin reuptake inhibitor, or SSRI. The FDA-approved low-dose paroxetine product for menopausal hot flashes is labeled as 7.5 mg by mouth at bedtime 7.

Venlafaxine is a serotonin-norepinephrine reuptake inhibitor, or SNRI, used in practice for vasomotor symptoms. SSRIs and SNRIs can cause nausea, sexual side effects, sleep changes, blood pressure changes, and drug interactions, so they should be matched to the person’s full medication list 10.

Gabapentin and clonidine

Gabapentin is a nerve-pain and seizure medicine that has evidence for hot flashes, especially at night for some patients. Side effects can include sleepiness, dizziness, swelling, and balance issues 10.

Clonidine is a blood pressure medicine that has been used for hot flashes, but benefit is modest and side effects can include dry mouth, dizziness, constipation, sleepiness, and low blood pressure 10.

Ospemifene and prasterone for vaginal symptoms

Ospemifene is an oral selective estrogen receptor modulator approved for moderate to severe painful sex due to menopause-related vulvar and vaginal atrophy. Its label includes warnings about endometrial cancer, cardiovascular disorders, and other risks that should be reviewed before use 8.

Prasterone is vaginal DHEA approved for moderate to severe painful sex due to menopause-related vulvar and vaginal atrophy. It is placed in the vagina, and its label describes local use and product-specific precautions 9.

How do compounded and bioidentical hormones compare with FDA-approved therapy?

Bioidentical hormones are hormones with the same chemical structure as hormones made by the body, such as estradiol and progesterone. The term can refer to FDA-approved products or to compounded hormone products made by a 503A compounding pharmacy 11.

Compounded medications can be useful when a clinician determines that a patient needs a formulation or dose not available as a manufactured product. They are not FDA-approved, which means FDA does not review them for safety, effectiveness, or manufacturing quality before they are dispensed 11.

At Chia, our safety focus is the licensed path: a licensed provider evaluates the patient, and prescriptions are dispensed by state-licensed US 503A pharmacies. We do not treat hormone therapy as a one-size-fits-all decision.

Are peptides, longevity therapies, or lifestyle changes helpful during menopause?

Lifestyle and longevity therapies may support overall health during midlife, but they do not replace menopause-specific treatment when symptoms are driven by estrogen loss. For hot flashes, vaginal dryness, and bone loss, the evidence base is strongest for the menopause-directed options discussed above 1.

Diet, exercise, sleep, and weight

Regular physical activity, strength training, calcium and vitamin D adequacy, smoking avoidance, and limiting alcohol can support bone, heart, sleep, and weight health after menopause. These steps may not stop hot flashes on their own, but they can lower other risks that rise with age 2.

Weight change is common around midlife, but it is not only about willpower. Sleep loss, lower activity, insulin resistance, muscle loss, medications, and life stress can all play a role 2.

Where NAD+ and sermorelin fit — and where they do not replace HRT

Chia offers NAD+ as an injection from $199/month and nasal spray from $129/month, and sermorelin as an injection from $199/month, nasal spray, or tablets. These are longevity-focused options for eligible patients, not treatments for hot flashes, vaginal dryness, or other menopause symptoms.

Sermorelin is a growth hormone-releasing hormone analog that stimulates the body’s growth-hormone axis, and NAD+ is a coenzyme involved in cellular energy metabolism. They may be discussed for broader goals like energy, recovery, or healthy aging, but they should not be used as substitutes for menopausal hormone therapy or non-hormonal menopause medicines when those are clinically indicated.

Herbal and complementary options

Some people try soy isoflavones, black cohosh, acupuncture, paced breathing, cooling devices, or supplements. Evidence is mixed, product quality varies, and supplements can interact with medicines or liver conditions, so it is worth discussing them with a clinician 10.

How can you get evaluated for menopause treatment at Chia?

Chia’s HRT for Women protocol is a 100% online path for eligible patients interested in systemic hormone therapy using oral estradiol plus immediate-release progesterone. The visit starts with a short health questionnaire and a licensed US provider review, and prescribing is not guaranteed.

Our HRT for Women protocol is the only menopause-relevant hormone protocol in Chia’s current catalog. Other treatments in this article, such as fezolinetant, vaginal estrogen, ospemifene, prasterone, gabapentin, clonidine, and testosterone for low libido, are included for education and are not listed as Chia offerings.

If prescribed, medication is compounded in the US by a state-licensed 503A pharmacy and shipped to your door. Dosing is provider-guided and adjusted over time, and patients can message their care team through the portal between visits.

You can start with Chia’s online eligibility quiz. A provider will decide whether the protocol is clinically appropriate based on your symptoms and health history.

Frequently asked questions

Keep reading

Peptides

Kisspeptin-10: How It Works, Uses, and What the Research Says

Peptides

Kisspeptin Peptide: What It Does, Evidence, Risks, and Access